8-K: Vaccinex Secures $4.5 Million in Funding Through Multiple Private Placements

Vaccinex, Inc. has successfully raised approximately $4.5 million through a registered direct offering and concurrent private placements, including the sale of preferred stock.

Summary

• Vaccinex, Inc. entered into a securities purchase agreement on March 27, 2024, to issue 193,000 shares of common stock and warrants to purchase 193,000 shares at a combined price of $7.77 per share and warrant, raising approximately $1.5 million.
• A concurrent private placement on March 27, 2024, involved the sale of 159,683 shares of common stock and warrants to purchase 159,683 shares at the same combined price, generating about $1.25 million.
• On March 29, 2024, the company sold preferred stock and warrants to the Alzheimers Drug Discovery Foundation for $1.75 million.
• The warrants from the first two transactions have an exercise price of $7.64 per share and expire on March 28, 2029, while the warrants from the third transaction have an exercise price of $7.64 per share and expire on March 29, 2029.
• The company has the right to call the warrants under certain conditions related to positive data from their Alzheimers disease study.
• The agreements include restrictions on the company issuing further shares of common stock or equivalents until June 26, 2024, and variable rate transactions until September 24, 2024.
• Executive officers and directors have agreed to a lock-up period until May 12, 2024, preventing them from selling or transferring their shares.
• The company has agreed to file a registration statement for the resale of the warrants and underlying shares by April 27, 2024, and to use commercially reasonable efforts to have it effective by May 27, 2024.
• The company also agreed to file a registration statement covering the resale of the preferred stock and underlying shares by June 27, 2024, and to use commercially reasonable efforts to have it effective within 30 days of filing.
• The Series A Preferred Stock is convertible into common stock at a price of $7.77 per share or the volume weighted average price of the Common Stock for the last three trading days prior to delivery of the conversion notice, whichever is greater.
• The Series A Preferred Stock carries a 5% cumulative dividend, increasing by 2% each year, not to exceed 12%, and is subject to a call right after a Positive Data Release.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company as it has successfully raised a significant amount of capital. However, the restrictions on future issuances and the call option on the warrants introduce some uncertainty. The sentiment is therefore moderately positive.

Positives

• The company successfully raised a significant amount of capital, approximately $4.5 million, through multiple transactions.
• The transactions included a registered direct offering, private placements, and the sale of preferred stock, diversifying the sources of funding.
• The warrants have a call option for the company based on positive data from their Alzheimers disease study, which could be beneficial if the study is successful.
• The lock-up agreements with executive officers and directors demonstrate confidence in the company's future.
• The preferred stock sale to the Alzheimers Drug Discovery Foundation provides additional funding and a potential strategic partnership.

Negatives

• The company is restricted from issuing further shares of common stock or equivalents until June 26, 2024, which could limit their flexibility.
• The company is restricted from variable rate transactions until September 24, 2024, which could limit their financing options.
• The warrants have a call option for the company, which could limit the potential upside for warrant holders.

Risks

• The company's ability to call the warrants is contingent on positive data from their Alzheimers disease study, which is not guaranteed.
• The restrictions on issuing further shares and variable rate transactions could limit the company's ability to raise additional capital if needed.
• The lock-up agreements could create selling pressure when they expire on May 12, 2024.
• The preferred stock has a cumulative dividend, which could increase the company's financial obligations over time.

Future Outlook

The company is focused on the results of its SIGNAL-AD Alzheimers disease study, which will determine the call option for the warrants and the conversion price of the preferred stock. The company is also working to register the resale of the securities.

Industry Context

The funding will support Vaccinex's ongoing research and development efforts, particularly in the area of Alzheimers disease. The company is operating in a competitive biotech landscape where securing funding is crucial for advancing clinical trials and bringing new therapies to market.

Comparison to Industry Standards

• The use of registered direct offerings and private placements is a common method for biotech companies to raise capital, especially those in the clinical stage.
• The terms of the warrants, including the exercise price and expiration date, are fairly standard for these types of transactions.
• The lock-up agreements are also typical for private placements, ensuring stability in the stock price for a certain period.
• The preferred stock sale to a foundation is a less common but not unheard of method of funding, and it can provide a strategic partnership.
• The cumulative dividend on the preferred stock is a common feature of preferred stock, but the increasing rate is less common and could be a burden if the company does not perform well.

Related Party Transactions

• Among the Private Placement Investors are FCMI Parent Co., which is controlled by Albert D. Friedberg, chair of the Board of Directors of the Company, and Vaccinex (Rochester), L.L.C., which is controlled by Maurice Zauderer, Ph.D., the Companys president, chief executive officer and a member of the Board.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability.
• Customers may benefit from the company's ability to continue research and development.
• Suppliers may benefit from the company's increased financial stability.
• Creditors may benefit from the company's increased financial stability.

Next Steps

• The company will file a registration statement for the resale of the warrants and underlying shares by April 27, 2024.
• The company will use commercially reasonable efforts to have the registration statement effective by May 27, 2024.
• The company will file a registration statement for the resale of the preferred stock and underlying shares by June 27, 2024.
• The company will use commercially reasonable efforts to have the registration statement effective within 30 days of filing.
• The company will continue to work on its SIGNAL-AD Alzheimers disease study and await results.

Key Dates

Keywords

private placement, registered direct offering, common stock, warrants, preferred stock, Alzheimers disease, capital raise, lock-up agreement, financial advisory agreement, pepinemab